Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Rises By 17.2%

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totalling 301,200 shares, a growth of 17.2% from the September 15th total of 256,900 shares. Based on an average trading volume of 4,630,000 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analysts Forecast Growth

GOVX has been the topic of a number of recent research reports. EF Hutton Acquisition Co. I upgraded GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Roth Mkm assumed coverage on GeoVax Labs in a research note on Tuesday, July 16th. They issued a “buy” rating and a $20.00 price target for the company. Noble Financial increased their price objective on shares of GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research note on Monday, August 19th. Roth Capital upgraded shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a report on Monday, August 12th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, GeoVax Labs presently has an average rating of “Buy” and an average target price of $12.67.

GeoVax Labs Stock Performance

NASDAQ GOVX traded down $0.01 on Wednesday, reaching $2.10. The company had a trading volume of 350,358 shares, compared to its average volume of 2,426,837. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18. The business has a 50 day moving average of $3.50 and a two-hundred day moving average of $2.53.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($1.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.57) by $0.58. The firm had revenue of $0.30 million for the quarter. During the same period last year, the firm posted ($3.30) EPS. Sell-side analysts expect that GeoVax Labs will post -5.1 EPS for the current year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.